39° Sunny

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition
STOCKING STUFFER CONTEST

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

22.05 +0.28 (+1.29%)

Streaming Delayed Price Updated: 9:56 AM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Enliven Therapeutics, Inc. - Common Stock

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

What's going on in today's pre-market session ↗

August 15, 2025

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Enliven Posts Loss Beat and Cash Surge ↗

August 13, 2025

Via The Motley Fool

Topics Intellectual Property

Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

July 02, 2025

Via Benzinga

Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ ↗

June 23, 2025

Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.

Via Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 13, 2025

Via Benzinga

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 08, 2025

Via Benzinga

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 31, 2024

Via Benzinga

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024 ↗

August 13, 2024

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 ↗

May 14, 2024

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program ↗

April 11, 2024

Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data.

Via Benzinga

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 11, 2024

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

Via Benzinga

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 11, 2024

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.

Via Benzinga

Topics Stocks

Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says ↗

April 09, 2024

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho...

Via Benzinga

Wall Street Mixed As Tech Stocks Fall, Fed Meeting Begins ↗

March 19, 2024

Stocks are scattered midday Tuesday, as investors digest the semiconductor sector's pullback that's being led by the shares of Nvidia.

Via Talk Markets

Topics Economy

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 19, 2024

Via Benzinga

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 19, 2024

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

Via Benzinga

National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday ↗

March 19, 2024

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 19, 2024

Via Benzinga

ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 ↗

March 14, 2024

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 26, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 16, 2024

Via Benzinga

7 A-Rated Biotech Stocks for Your August Buy List ↗

August 17, 2023

Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge.

Via InvestorPlace

Bears Reload On Mobileye After Sharp Gains In Stock Price ↗

May 28, 2023

Short interest on Mobileye Global fell from 23.9% to 21.2% in the week following the company’s Q1 results and FY23 guidance cut on April 27. However, Mobileye shares are up 31% from those lows over the...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023 ↗

March 29, 2023

Via Benzinga

7 Biotech Stocks Sitting in the Sweet Spot ↗

March 24, 2023

Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023 ↗

March 03, 2023

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

Headline News about Enliven Therapeutics, Inc. - Common Stock

Sections

Services